BRIEF—Incyte submits pemigatinib for EU approval

Incyte has applied for European marketing authorization for pemigatinib, for the treatment of certain adults with locally advanced or metastatic cholangiocarcinoma.

The application is based on data from the FIGHT-202 study. Cholangiocarcinoma is a rare cancer that forms in the bile duct.

In November 2019, the US regulator commenced reviewing the therapy in this indication, under the Priority Review scheme. A decision from the FDA is expected by May 30, 2020.